<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118505</article-id><article-id pub-id-type="publisher-id">ACM-44561</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_60146850.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  老年肝癌患者行肝癌根治术的临床特点及安全性分析
  Clinical Characteristics and Safety Analysis of Radical Resection of Liver Cancer in Elderly Patients with Liver Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>明</surname><given-names>军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>成武</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆市合川区中医院外一科，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3469</fpage><lpage>3473</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：分析行肝癌根治术的老年肝癌患者的临床特点及安全性。方法：选2019.01~2020.01重庆市合川区中医院外一科收治的85例行肝癌根治术的老年肝癌患者进行研究，根据年龄分为2组，对照组(n = 68，非老年组)，试验组(n = 17，老年组)，对比一般资料、术后疗效等相关指标。结果：实验组与对照组性别、病程、甲胎蛋白 &gt; 400 μg/L发生率、术中出血量、术后并发症发生率对比无显著差异，P &gt; 0.05。试验组乙型肝炎表面抗原、乙型肝炎病毒及丙型肝炎病毒感染率、肝硬化发生率显著低于对照组，P &lt; 0.05。结论：行肝癌根治术的老年肝癌患者安全性与非老年患者一致，但肝癌根治术可提高老年肝癌患者预期寿命。
   Objective: To analyze the clinical characteristics and safety of elderly patients with liver cancer undergoing radical resection of liver cancer. Methods: From January 2019 to January 2020, 85 elderly patients with liver cancer who underwent radical resection of liver cancer and were admitted to the First Department of Chongqing Hechuan Traditional Chinese Medicine Hospital were selected for the study. They were divided into 2 groups according to their age, the control group (n = 68, non-elderly group), and the trial group (n = 17, elderly group), to compare general data, postoperative efficacy and other related indicators. Results: There were no significant differences between the experimental group and the control group in terms of gender, course of disease, incidence of alpha-fetoprotein &gt; 400 μg/L, intraoperative blood loss, and incidence of postoperative complications, P &gt; 0.05. The infection rate of hepatitis B surface antigen, hepatitis B virus and hepatitis C virus, and the incidence of liver cirrhosis in the experimental group were significantly lower than those in the control group, P &lt; 0.05. Conclusion: The safety of elderly liver cancer patients undergoing radical liver cancer surgery is the same as that of non-elderly patients, but radical liver cancer surgery can increase the life expectancy of elderly liver cancer patients.
 
</p></abstract><kwd-group><kwd>肝癌根治术，老年，肝癌，临床特点，安全性, Radical Resection of Liver Cancer</kwd><kwd> Elderly</kwd><kwd> Liver Cancer</kwd><kwd> Clinical Features</kwd><kwd> Safety</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析行肝癌根治术的老年肝癌患者的临床特点及安全性。方法：选2019.01~2020.01重庆市合川区中医院外一科收治的85例行肝癌根治术的老年肝癌患者进行研究，根据年龄分为2组，对照组(n = 68，非老年组)，试验组(n = 17，老年组)，对比一般资料、术后疗效等相关指标。结果：实验组与对照组性别、病程、甲胎蛋白 &gt; 400 μg/L发生率、术中出血量、术后并发症发生率对比无显著差异，P &gt; 0.05。试验组乙型肝炎表面抗原、乙型肝炎病毒及丙型肝炎病毒感染率、肝硬化发生率显著低于对照组，P &lt; 0.05。结论：行肝癌根治术的老年肝癌患者安全性与非老年患者一致，但肝癌根治术可提高老年肝癌患者预期寿命。</p></sec><sec id="s2"><title>关键词</title><p>肝癌根治术，老年，肝癌，临床特点，安全性</p></sec><sec id="s3"><title>Clinical Characteristics and Safety Analysis of Radical Resection of Liver Cancer in Elderly Patients with Liver Cancer<sup> </sup></title><p>Jun Ming, Chengwu Yang</p><p>The First Department of Chongqing Hechuan Traditional Chinese Medicine Hospital, Chongqing</p><p><img src="//html.hanspub.org/file/22-1572466x4_hanspub.png?20210816170456395" /></p><p>Received: Jul. 11<sup>th</sup>, 2021; accepted: Aug. 9<sup>th</sup>, 2021; published: Aug. 16<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/22-1572466x5_hanspub.png?20210816170456395" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the clinical characteristics and safety of elderly patients with liver cancer undergoing radical resection of liver cancer. Methods: From January 2019 to January 2020, 85 elderly patients with liver cancer who underwent radical resection of liver cancer and were admitted to the First Department of Chongqing Hechuan Traditional Chinese Medicine Hospital were selected for the study. They were divided into 2 groups according to their age, the control group (n = 68, non-elderly group), and the trial group (n = 17, elderly group), to compare general data, postoperative efficacy and other related indicators. Results: There were no significant differences between the experimental group and the control group in terms of gender, course of disease, incidence of alpha-fetoprotein &gt; 400 μg/L, intraoperative blood loss, and incidence of postoperative complications, P &gt; 0.05. The infection rate of hepatitis B surface antigen, hepatitis B virus and hepatitis C virus, and the incidence of liver cirrhosis in the experimental group were significantly lower than those in the control group, P &lt; 0.05. Conclusion: The safety of elderly liver cancer patients undergoing radical liver cancer surgery is the same as that of non-elderly patients, but radical liver cancer surgery can increase the life expectancy of elderly liver cancer patients.</p><p>Keywords:Radical Resection of Liver Cancer, Elderly, Liver Cancer, Clinical Features, Safety</p><disp-formula id="hanspub.44561-formula8"><graphic xlink:href="//html.hanspub.org/file/22-1572466x6_hanspub.png?20210816170456395"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/22-1572466x7_hanspub.png?20210816170456395" /> <img src="//html.hanspub.org/file/22-1572466x8_hanspub.png?20210816170456395" /></p></sec><sec id="s5"><title>1. 引言</title><p>肝癌是我国最常见的恶性肿瘤之一，随着人口老龄化发展，我国老年肝癌的发病率呈不断上升趋势，已造成严重的社会和医疗负担 [<xref ref-type="bibr" rid="hanspub.44561-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44561-ref2">2</xref>]。而随着近年诊疗水平的提升、人们体检意识的增强、人均寿命的延长，老年(医学界将≥60岁患者设定为老年)肝癌检出率逐年升高 [<xref ref-type="bibr" rid="hanspub.44561-ref3">3</xref>]。而肝癌的治疗仍是医学界的难题之一，目前常见的治疗方式主要分为手术治疗和非手术治疗。肝癌根治性切除术作为临床上最有效的治疗方式 [<xref ref-type="bibr" rid="hanspub.44561-ref4">4</xref>]，可以明显改善患者当前状况和生存预期，但针对老年性肝癌患者，因其合并起病隐匿、基础疾病多、心肺功能差、多为中晚期、术后并发症较多等特点 [<xref ref-type="bibr" rid="hanspub.44561-ref5">5</xref>]，目前临床对老年肝癌患者是否实施手术存在争议。随着近年医疗技术及护理水平明显提升，老年肝癌患者术后并发症得到有效控制，选择根治性肝癌切除术的患者越来越多，但其手术的安全性仍是需要重视的问题。本文选择85例2019.01~2020.02区间收治行肝癌根治术的老年肝癌患者进行研究，分析行肝癌根治术的老年肝癌患者的临床特点及安全性，以期为老年肝癌患者的治疗提供依据。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>纳入研究85例行肝癌根治术的老年肝癌患者均选自2019.01~2020.02区间。其中47例男、38例女，年龄42~80岁，均值(60.52 &#177; 15.14)岁。</p><p>纳入超声、CT扫描确诊为肝癌者；签署知情同意书者；肿瘤可完整切除者；ASA分级I-III级者。排除精神疾病者；肝外转移者；肿瘤弥漫全肝无法全部切除者。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>采集81例患者性别、病程、甲胎蛋白 &gt; 400 μg/L发生率、术中出血量、术后并发症发生率、乙型肝炎表面抗原阳性、乙型肝炎病毒及丙型肝炎病毒感染率、肝硬化发生率等临床资料(如表1所示)。本研究获医院医学伦理委员会审批，患者及家属均签署知情同意书。</p></sec><sec id="s6_3"><title>2.3. 统计学方法</title><p>借助SPSS22.0分析，t、平方差表示计量资料，%、卡方表示计数资料，P值表示检验结果。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般资料</title><p>试验组、对照组性别、病程、甲胎蛋白 &gt; 400 μg/L发生率、术中出血量对比无显著差异，P &gt; 0.05。试验组乙型肝炎表面抗原阳性、乙型肝炎病毒及丙型肝炎病毒感染率、肝硬化发生率显著低于对照组，P &lt; 0.05。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Normal informatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >一般资料</th><th align="center" valign="middle" >试验组(n = 17)</th><th align="center" valign="middle" >对照组(n = 68)</th><th align="center" valign="middle" >X<sup>2</sup>/t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >性别(男/女)</td><td align="center" valign="middle" >10/7</td><td align="center" valign="middle" >37/31</td><td align="center" valign="middle" >0.1071</td><td align="center" valign="middle" >0.7435</td></tr><tr><td align="center" valign="middle" >病程(年)</td><td align="center" valign="middle" >0.32 &#177; 0.15</td><td align="center" valign="middle" >0.36 &#177; 0.11</td><td align="center" valign="middle" >1.2421</td><td align="center" valign="middle" >0.2177</td></tr><tr><td align="center" valign="middle" >甲胎蛋白 &gt; 400 μg/L</td><td align="center" valign="middle" >29.42% (05/17)</td><td align="center" valign="middle" >36.76% (25/68)</td><td align="center" valign="middle" >0.3220</td><td align="center" valign="middle" >0.5704</td></tr><tr><td align="center" valign="middle" >肝硬化</td><td align="center" valign="middle" >23.53% (4/17)</td><td align="center" valign="middle" >91.18% (62/68)</td><td align="center" valign="middle" >35.8573</td><td align="center" valign="middle" >0.0000</td></tr><tr><td align="center" valign="middle" >乙型肝炎表面抗原阳性</td><td align="center" valign="middle" >35.29% (6/17)</td><td align="center" valign="middle" >70.59% (48/68)</td><td align="center" valign="middle" >7.3118</td><td align="center" valign="middle" >0.0007</td></tr><tr><td align="center" valign="middle" >乙型肝炎病毒及丙型肝炎病毒感染率</td><td align="center" valign="middle" >52.94% (9/17)</td><td align="center" valign="middle" >95.59% (65/68)</td><td align="center" valign="middle" >21.9549</td><td align="center" valign="middle" >0.0000</td></tr><tr><td align="center" valign="middle" >术中出血量(ml)</td><td align="center" valign="middle" >381.62 &#177; 70.52</td><td align="center" valign="middle" >430.05 &#177; 98.15</td><td align="center" valign="middle" >1.9110</td><td align="center" valign="middle" >0.0595</td></tr></tbody></table></table-wrap><p>表1. 一般资料</p></sec><sec id="s7_2"><title>3.2. 预后效果</title><p>试验组、对照组术后并发症率(23.53% vs. 17.65%)、肝内复发率(58.82% vs. 52.94%)、肝外复发率(23.53% vs. 29.42%)、肝内及肝外复发率(17.65% vs. 17.65%)对比无显著差异，P &gt; 0.05。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Prognostic effect (%</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >一般资料</th><th align="center" valign="middle" >试验组(n = 17)</th><th align="center" valign="middle" >对照组(n = 68)</th><th align="center" valign="middle" >X<sup>2</sup>/t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >并发症发生率</td><td align="center" valign="middle" >23.53% (4/17)</td><td align="center" valign="middle" >17.65% (12/68)</td><td align="center" valign="middle" >0.3080</td><td align="center" valign="middle" >0.5789</td></tr><tr><td align="center" valign="middle" >肝内复发率</td><td align="center" valign="middle" >58.82% (10/17)</td><td align="center" valign="middle" >52.94% (36/68)</td><td align="center" valign="middle" >0.1895</td><td align="center" valign="middle" >0.6634</td></tr><tr><td align="center" valign="middle" >肝外复发率</td><td align="center" valign="middle" >23.53% (4/17)</td><td align="center" valign="middle" >29.42% (20/68)</td><td align="center" valign="middle" >0.0054</td><td align="center" valign="middle" >0.9417</td></tr><tr><td align="center" valign="middle" >肝内及肝外复发率</td><td align="center" valign="middle" >17.65% (12/68)</td><td align="center" valign="middle" >17.65% (12/68)</td><td align="center" valign="middle" >0.0000</td><td align="center" valign="middle" >1.0000</td></tr></tbody></table></table-wrap><p>表2. 预后效果(%)</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>肝细胞癌(以下简称肝癌)是最常见的原发性肝癌，约占原发性肝癌的90%，据世界卫生组织国际癌症研究机构发布的2020年最新全球负担数据 [<xref ref-type="bibr" rid="hanspub.44561-ref6">6</xref>] 显示，肝癌高居我国癌症新发病率第5位，达41万例，死亡率第2位，达39万例。原发性肝癌发生的病因和发病机制尚未完全阐明，目前已知的危险因素 [<xref ref-type="bibr" rid="hanspub.44561-ref7">7</xref>] 包括病毒感染、个人行为、生活方式、环境和遗传等多方面因素，包括HBV感染、HCV感染、酒精摄入、非酒精性脂肪性肝病/代谢相关性脂肪性肝病、自身免疫性肝病及遗传代谢性肝病、或伴发2型糖尿病及黄曲霉毒素暴露等。</p><p>上述负担数据也显示，我国的肝癌由HBV感染引起的比例高达92.05%。因此，对于慢性乙肝患者应积极有效地接受抗病毒治疗，以降低肝癌的发生率，提高肝癌患者的预期寿命。既往大量研究显示 [<xref ref-type="bibr" rid="hanspub.44561-ref8">8</xref>]，乙型病毒肝炎多发于儿童时期，随着病情进展出现肝硬化、肝癌，肝癌总体预后效果较差，导致部分患者难以生存至70岁，这就是本研究中老年肝癌患者乙型肝炎表面抗原阳性35.29%、肝硬化23.53%、乙型肝炎病毒及丙型肝炎病毒感染率52.94%等病因较对照组低的主要原因。目前，临床上主要采用手术治疗肝癌，肝癌根治性切除术是肝癌患者最有效的一种治疗手段，能够明显改善肝癌患者的预后 [<xref ref-type="bibr" rid="hanspub.44561-ref9">9</xref>]。但针对老年患者，因其身体基本情况的复杂性，即使具有手术指征，手术的安全性将是不得不考虑的一个方面。以前，有相关报道提出，肝癌根治性切除术后高复发率特别是早期复发严重影响治疗效果，且复发是影响肝癌患者根治性肝切除术后长期生存的一项重要因素 [<xref ref-type="bibr" rid="hanspub.44561-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44561-ref11">11</xref>]。但在本次研究显示，在85例均实施肝癌根治术治疗的患者中，试验组17人，对照组68人，两组术后并发症率、肝内复发率、肝外复发率、肝内及肝外复发率无明显差异(如表2所示)。证实老年肝癌患者术前只要严格掌握手术禁忌症、适应症，实施肝癌切除术可达到理想效果与安全性。此外，随着微创技术发展，腹腔镜切除术因具有出血量少、并发症少等优势，逐渐成为治疗肝癌首选方案，进一步提高了老年患者性根治性肝癌切除术的安全性，但尚无研究证实微创手术预后与开放手术一致 [<xref ref-type="bibr" rid="hanspub.44561-ref12">12</xref>]。</p></sec><sec id="s9"><title>5. 结论</title><p>综上，老年肝癌患者实施肝癌根治术治疗过程中虽然有一定的风险，但只要严格把握手术指征，做好充足术前准备，可使术后复发率与并发症发生率与非老年患者类似，而手术治疗可以提高老年肝癌患者预期寿命。<sup> </sup></p></sec><sec id="s10"><title>文章引用</title><p>明 军,杨成武. 老年肝癌患者行肝癌根治术的临床特点及安全性分析Clinical Characteristics and Safety Analysis of Radical Resection of Liver Cancer in Elderly Patients with Liver Cancer[J]. 临床医学进展, 2021, 11(08): 3469-3473. https://doi.org/10.12677/ACM.2021.118505</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44561-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rao, C.V., Asch, A.S. and Yamada, H.Y. (2017) Frequently Mutated Genes/Pathways and Genomic Instability as Prevention Targets in Liver Cancer. Carcinogenesis, 38, 2-11. &lt;br&gt;https://doi.org/10.1093/carcin/bgw118</mixed-citation></ref><ref id="hanspub.44561-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">赵姣萍, 许文芳. 预测老年早期肝癌患者术后发生肝衰竭的列线图模型建立[J]. 浙江中西医结合杂志, 2020, 30(9): 767-770.</mixed-citation></ref><ref id="hanspub.44561-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">武伟, 李国兰, 周洪伟, 等. 行肝癌根治术的老年肝癌患者临床特点及长期预后研究[J]. 中国全科医学, 2016, 19(14): 1663-1666.</mixed-citation></ref><ref id="hanspub.44561-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">海峡两岸医药卫生交流协会肿瘤防治专家委员会. 肝癌肝切除围手术期管理中国专家共识(2021年版)[J]. 中华肿瘤杂志, 2021, 43(4): 414-430.</mixed-citation></ref><ref id="hanspub.44561-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">杩奇, 朱瑞萍. 老年原发性肝癌临床特点与病理特点的探讨[J]. 中国现代药物应用, 2020, 14(7): 33-35.</mixed-citation></ref><ref id="hanspub.44561-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">IARC (2020) Latest Global Cancer Data: Cancer Burden Rises to 19.3 Million New Cases and 10.0 Million Cancer Deaths in 2020.</mixed-citation></ref><ref id="hanspub.44561-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版) [J]. 中华肝脏病杂志, 2021, 29(3): 216-226.</mixed-citation></ref><ref id="hanspub.44561-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">孙雨, 梅苹, 宋晓伟, 等. 320排容积CT灌注成像在36例小肝癌血流灌注特点及病理分化程度评估中的临床价值[J]. 延边大学医学学报, 2019, 42(1): 44-46.</mixed-citation></ref><ref id="hanspub.44561-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">兆勇, 李井野. 老年肝癌根治性切除术后肝癌复发的高危因素分析[J]. 现代肿瘤医学, 2020, 28(21): 3745-3748.</mixed-citation></ref><ref id="hanspub.44561-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Akinyemiju, T., Abera, S., Ahmed, M., et al. (2017) The Burden of Primary Liver Cancer and Underlying Etiologies from 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015. JAMA Oncology, 3, 1683-1691. &lt;br&gt;https://doi.org/10.1001/jamaoncol.2017.3055</mixed-citation></ref><ref id="hanspub.44561-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">何建新, 王永波, 何文平, 张坤, 谭龙. 射频消融术辅助部分肝切除术治疗原发性肝癌的效果及复发率随访研究[J]. 肝胆外科杂志, 2017, 25(2): 126-129.</mixed-citation></ref><ref id="hanspub.44561-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">王华利, 熊清芳, 杨永峰. 279例老年原发性肝癌临床特点及预后影响因素分析[J]. 实用老年医学, 2017, 31(12): 1135-1137.</mixed-citation></ref></ref-list></back></article>